JP2025506098A - 結晶質プロスタサイクリン（ｉｐ）受容体アゴニストおよびその使用 - Google Patents

結晶質プロスタサイクリン（ｉｐ）受容体アゴニストおよびその使用 Download PDF

Info

Publication number
JP2025506098A
JP2025506098A JP2024543285A JP2024543285A JP2025506098A JP 2025506098 A JP2025506098 A JP 2025506098A JP 2024543285 A JP2024543285 A JP 2024543285A JP 2024543285 A JP2024543285 A JP 2024543285A JP 2025506098 A JP2025506098 A JP 2025506098A
Authority
JP
Japan
Prior art keywords
pattern
xrpd
crystalline form
lalinepag
ralinepag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506098A5 (https=
Inventor
ファレス，ケネス
Original Assignee
ユナイテッド セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレイション filed Critical ユナイテッド セラピューティクス コーポレイション
Publication of JP2025506098A publication Critical patent/JP2025506098A/ja
Publication of JP2025506098A5 publication Critical patent/JP2025506098A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024543285A 2022-02-15 2023-02-14 結晶質プロスタサイクリン（ｉｐ）受容体アゴニストおよびその使用 Pending JP2025506098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310469P 2022-02-15 2022-02-15
US63/310,469 2022-02-15
PCT/US2023/013032 WO2023158634A1 (en) 2022-02-15 2023-02-14 Crystalline prostacyclin (ip) receptor agonist and uses thereof

Publications (2)

Publication Number Publication Date
JP2025506098A true JP2025506098A (ja) 2025-03-07
JP2025506098A5 JP2025506098A5 (https=) 2026-02-20

Family

ID=87578956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543285A Pending JP2025506098A (ja) 2022-02-15 2023-02-14 結晶質プロスタサイクリン（ｉｐ）受容体アゴニストおよびその使用

Country Status (9)

Country Link
US (2) US12098116B2 (https=)
EP (1) EP4479374A1 (https=)
JP (1) JP2025506098A (https=)
KR (1) KR20240149924A (https=)
CN (1) CN118922402A (https=)
AU (1) AU2023222747A1 (https=)
CA (1) CA3248736A1 (https=)
IL (1) IL314717A (https=)
WO (1) WO2023158634A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
US20240139207A1 (en) 2022-10-31 2024-05-02 United Therapeutics Corporation Methods for treating pulmonary hypertension
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945530A1 (de) 1979-11-10 1981-06-04 Chemische Werke Hüls AG, 4370 Marl Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide
JPH03160438A (ja) 1989-11-20 1991-07-10 Konica Corp ハロゲン化銀カラー写真感光材料
EP0442448A3 (en) 1990-02-13 1992-08-12 Bristol-Myers Squibb Company Heterocyclic carboxylic acids and esters
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
JPH06329598A (ja) 1993-05-19 1994-11-29 Daicel Chem Ind Ltd エステルの製造方法
DE4318889A1 (de) 1993-06-07 1994-12-08 Bayer Ag Verfahren zur Herstellung von organischen Carbamaten
TW282456B (https=) 1994-03-10 1996-08-01 Fujisawa Yakusin Kogyo Kk
JPH11269138A (ja) 1998-03-20 1999-10-05 Mitsubishi Paper Mills Ltd 有機塩基発生剤
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
KR100523119B1 (ko) 2000-03-16 2005-10-20 에프. 호프만-라 로슈 아게 Ｉｐ 길항제로서의 카복실산 유도체
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
CN101284773A (zh) 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CN1735598A (zh) 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
RU2351590C2 (ru) 2003-02-10 2009-04-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения диариламина
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
JP4339890B2 (ja) 2003-09-22 2009-10-07 エフ．ホフマン−ラ ロシュ アーゲー アミノアルキルアミド置換シクロヘキシル誘導体
JP4402413B2 (ja) 2003-09-29 2010-01-20 財団法人２１あおもり産業総合支援センター Ｕ字型化合物およびこれを含む液晶組成物
DE102004006785A1 (de) 2004-02-11 2005-09-08 Mayr, Herbert, Prof. Dr. Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
JP4792731B2 (ja) 2004-11-12 2011-10-12 Ｄｉｃ株式会社 重合性液晶組成物及び当該組成物の硬化物
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
JP2007161867A (ja) 2005-12-14 2007-06-28 Toyo Ink Mfg Co Ltd インキ組成物
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
WO2009117095A1 (en) 2008-03-18 2009-09-24 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
US20110224262A1 (en) 2008-11-26 2011-09-15 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
ES2548882T3 (es) 2008-12-08 2015-10-21 Arena Pharmaceuticals, Inc. Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos
WO2011037613A1 (en) 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
US10537546B2 (en) 2014-10-23 2020-01-21 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
US12377067B2 (en) 2016-11-10 2025-08-05 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents
IL268997B2 (en) 2017-03-01 2023-09-01 Arena Pharm Inc Preparations containing pgi2 receptor agonists and processes for their preparation
CA3072079A1 (en) 2017-08-07 2019-02-14 Arena Pharmaceuticals, Inc. Methods of treatment
EP3796902A1 (en) 2018-05-16 2021-03-31 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
WO2020048299A1 (zh) 2018-09-06 2020-03-12 广东东阳光药业有限公司 药物共晶体及其制备方法
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
AU2023236147A1 (en) 2022-03-17 2024-09-19 United Therapeutics Corporation Ralinepag prodrugs and uses thereof

Also Published As

Publication number Publication date
US20240409503A1 (en) 2024-12-12
AU2023222747A1 (en) 2024-08-22
KR20240149924A (ko) 2024-10-15
CN118922402A (zh) 2024-11-08
IL314717A (en) 2024-10-01
CA3248736A1 (en) 2023-08-24
US12098116B2 (en) 2024-09-24
WO2023158634A1 (en) 2023-08-24
US20230406815A1 (en) 2023-12-21
EP4479374A1 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
JP2025506098A (ja) 結晶質プロスタサイクリン（ｉｐ）受容体アゴニストおよびその使用
Moinuddin et al. Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile
KR100529658B1 (ko) 발사르탄 염
JP2021523918A (ja) Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
TWI718104B (zh) AHU-377結晶型游離酸、半鈣鹽、α-苯乙胺鹽及其製備方法和應用
AU2016344627B2 (en) Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine H4 receptor (H4) mediated diseases and conditions
AU2018227842B2 (en) Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
CN107001275A (zh) Nk‑1拮抗剂的晶型
JP2025165933A (ja) サルカルディン塩
BR112019012340A2 (pt) sais cristalinos e polimorfos de um antagonista p2x3
US12187700B2 (en) Polymorphs and cocrystals of a cardiac troponin activator
TW201803853A (zh) ２，６－二甲基嘧啶酮衍生物的鹽及其用途
CN111635315A (zh) 一种解热镇痛药物及其制备方法和应用
CN109311820B (zh) 2,6-二甲基嘧啶酮衍生物的盐及其用途
TWI607006B (zh) 細胞凋亡蛋白抑制劑之固體口服調配物及晶型
US12433865B2 (en) Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
US10654859B2 (en) Methanesulfonate polymorph of 5-type phosphodiesterase inhibitor and preparation method and applications thereof
WO2024115727A1 (en) Crystal form of a pde3/4 inhibitor
CN120390744A (zh) Lpa1拮抗剂的结晶形式
WO2022236139A1 (en) Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods
KR20260014613A (ko) 아미노 퀴나졸린 유도체의 염
HK40068824A (en) Polymorphs and cocrystals of a cardiac troponin activator
HK40072274A (en) Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
WO2019072130A1 (zh) 一种1,2,4-三氮唑类化合物
JPH029816A (ja) スパガリン類製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260212